EGFR and glioblastoma: The in vitro results demonstrated the ability of panitumumab to improve nanoparticles’ internalization in GBM cells through its recognition by EGFR, with a subsequent increase in the antitumoral activity of temozolomide-loaded nanoparticles [95].